- Home
- LFWD vs TRAW Comparison
LFWD vs TRAW Comparison
Compare LFWD & TRAW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LFWD
- TRAW
- Stock Information
- Founded
- LFWD 2001
- TRAW 1998
- Country
- LFWD Israel
- TRAW United States
- Employees
- LFWD N/A
- TRAW N/A
- Industry
- LFWD
- TRAW
- Sector
- LFWD
- TRAW
- Exchange
- LFWD NYSE
- TRAW NYSE
- Market Cap
- LFWD 10.5M
- TRAW 8.6M
- IPO Year
- LFWD 2014
- TRAW 2013
- Fundamental
- Price
- LFWD $0.78
- TRAW $1.58
- Analyst Decision
- LFWD Strong Buy
- TRAW
- Analyst Count
- LFWD 3
- TRAW 0
- Target Price
- LFWD $9.00
- TRAW N/A
- AVG Volume (30 Days)
- LFWD 804.6K
- TRAW 71.7K
- Earning Date
- LFWD 08-14-2025
- TRAW 08-14-2025
- Dividend Yield
- LFWD N/A
- TRAW N/A
- EPS Growth
- LFWD N/A
- TRAW N/A
- EPS
- LFWD N/A
- TRAW N/A
- Revenue
- LFWD $25,414,000.00
- TRAW $227,000.00
- Revenue This Year
- LFWD $12.04
- TRAW $3.81
- Revenue Next Year
- LFWD $40.58
- TRAW $30.43
- P/E Ratio
- LFWD N/A
- TRAW N/A
- Revenue Growth
- LFWD 41.92
- TRAW 0.44
- 52 Week Low
- LFWD $0.50
- TRAW $0.97
- 52 Week High
- LFWD $4.77
- TRAW $19.44
- Technical
- Relative Strength Index (RSI)
- LFWD 43.98
- TRAW 50.55
- Support Level
- LFWD $0.70
- TRAW $1.47
- Resistance Level
- LFWD $0.84
- TRAW $1.73
- Average True Range (ATR)
- LFWD 0.07
- TRAW 0.10
- MACD
- LFWD 0.03
- TRAW 0.01
- Stochastic Oscillator
- LFWD 44.88
- TRAW 50.00
About LFWD REWALK ROBOTICS LTD
Lifeward Ltd is a medical device company that designs, develops, and commercializes life-changing solutions that span the continuum of care in physical rehabilitation and recovery, delivering functional and health benefits in clinical settings as well as in the home and community. Its product offerings are the ReWalk Exoskeleton, the ReStore Exo-Suit, the MyoCycle FES bikes, and AlterG Anti-Gravity systems. It operates through markets in the United States, Israel, and Germany.
About TRAW TRAWS PHARMA INC
Traws Pharma Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. It is advancing novel investigational antiviral agents that have potent activity against difficult-to-treat or resistant virus strains that threaten human health. Its product candidates are Tivoxavir marboxil, Ratutrelvir, and Narazaciclib.